Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; and CAP-2003, and allogeneic cardiosphere-derived cells-exosomes, which is in preclinical trial to treat DMD. It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.

Capricor Therapeutics Inc.

An announcement from Caprock Mining Corp ( ($TSE:CAPR) ) is now available. Caprock Mining Corp. has successfully closed its non-brokered financing,...

Caprock Mining Corp. Completes Financing and Confirms Destiny Option Payment

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Capricor Therapeutics, with a price target of $45.00. Ten...

Piper Sandler Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)

In a report released today, Boobalan Pachaiyappan from Roth MKM reiterated a Buy rating on Capricor Therapeutics, with a price target of $54.00. Pa...

Roth MKM Remains a Buy on Capricor Therapeutics (CAPR)

The latest announcement is out from Capricor Therapeutics ( ($CAPR) ). On December 5, 2025, Capricor Therapeutics announced the pricing of a public...

Capricor Therapeutics Announces $150 Million Public Offering

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Capricor Therapeutics (CAPR – Research Report) and I...

Analysts’ Top Healthcare Picks: Capricor Therapeutics (CAPR), Insmed (INSM)

In a report released today, Matthew Venezia from Alliance Global Partners reiterated a Buy rating on Capricor Therapeutics, with a price target of ...

Alliance Global Partners Remains a Buy on Capricor Therapeutics (CAPR)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Capricor Therapeutics, with a price target of $60.00. ...

Capricor Therapeutics (CAPR) Receives a Buy from H.C. Wainwright

Investors on the lookout for the latest earnings reports, analyst updates, and economic data will find it in our daily wrap-up.


Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!

Capricor Therapeutics stock soared on Wednesday after the company revealed strong Phase 3 study results.


Here’s Why Capricor Therapeutics Stock (CAPR) Took Off Today

Capricor Therapeutics ( ($CAPR) ) just unveiled an update. On December 3, 2025, Capricor Therapeutics provided an update on the top-line results fr...

Capricor Therapeutics Reports Positive HOPE-3 Trial Results

Capricor Therapeutics ( ($CAPR) ) has provided an announcement. On December 3, 2025, Capricor Therapeutics announced positive topline results from ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CAPR	$26.02	-4.27%	1.78M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CAPR	$26.02	-4.3%	1.78M
3
4
5
6

CAPR

CAPR

Get Capricor Therapeutics Inc. Data in Excel

Get Capricor Therapeutics Inc. Data in Excel